Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Liabilities and Shareholders Equity: 2017-2025

Historic Liabilities and Shareholders Equity for Protagonist Therapeutics (PTGX) over the last 9 years, with Sep 2025 value amounting to $701.7 million.

  • Protagonist Therapeutics' Liabilities and Shareholders Equity rose 16.20% to $701.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 31.77%. This contributed to the annual value of $744.7 million for FY2024, which is 108.05% up from last year.
  • As of Q3 2025, Protagonist Therapeutics' Liabilities and Shareholders Equity stood at $701.7 million, which was down 2.27% from $718.0 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Liabilities and Shareholders Equity ranged from a high of $744.7 million in Q4 2024 and a low of $239.9 million during Q1 2023.
  • Its 3-year average for Liabilities and Shareholders Equity is $545.7 million, with a median of $614.6 million in 2024.
  • As far as peak fluctuations go, Protagonist Therapeutics' Liabilities and Shareholders Equity tumbled by 31.13% in 2023, and later surged by 162.35% in 2024.
  • Protagonist Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $347.7 million in 2021, then declined by 28.69% to $247.9 million in 2022, then spiked by 44.38% to $358.0 million in 2023, then skyrocketed by 108.05% to $744.7 million in 2024, then climbed by 16.20% to $701.7 million in 2025.
  • Its last three reported values are $701.7 million in Q3 2025, $718.0 million for Q2 2025, and $742.1 million during Q1 2025.